Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification
Authors:
- 6 December 2013
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2013 (1) , 575-583
Abstract
MYC is a potent oncogene initially identified as the target of the t(8;14)(q24;q32) chromosome translocation in Burkitt lymphoma. MYC gene alterations have been identified in other mature B-cell neoplasms that are usually associated with an aggressive clinical behavior. Most of these tumors originate in cells that do not normally express MYC protein. The oncogenic events leading to MYC up-regulation seem to overcome the inhibitory effect of physiological repressors such as BCL6 or BLIMP1. Aggressive lymphomas frequently carry additional oncogenic alterations that cooperate with MYC dysregulation, likely counteracting its proapoptotic function. The development of FISH probes and new reliable antibodies have facilitated the study of MYC gene alterations and protein expression in large series of patients, providing new clinical and biological perspectives regarding MYC dysregulation in aggressive lymphomas. MYC gene alterations in large B-cell lymphomas are frequently associated with BCL2 or BCL6 translocations conferring a very aggressive behavior. Conversely, MYC protein up-regulation may occur in tumors without apparent gene alterations, and its association with BCL2 overexpression also confers a poor prognosis. In this review, we integrate all of this new information and discuss perspectives, challenges, and open questions for the diagnosis and management of patients with MYC-driven aggressive B-cell lymphomas.Keywords
This publication has 86 references indexed in Scilit:
- The genetic landscape of mutations in Burkitt lymphomaNature Genetics, 2012
- MYC on the Path to CancerCell, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Myc overexpression brings out unexpected antiapoptotic effects of miR-34aOncogene, 2011
- Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumorsGenes, Chromosomes and Cancer, 2008
- Widespread microRNA repression by Myc contributes to tumorigenesisNature Genetics, 2007
- Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesisThe EMBO Journal, 2007
- Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomasLeukemia, 2007
- The great MYC escape in tumorigenesisCancer Cell, 2005
- Evasion of the p53 tumour surveillance network by tumour-derived MYC mutantsNature, 2005